Wolfgang Miesbach: Jan Astermark at the BIC 2025 Presented Potentially the First Oral FVIII Mimetic Treatment for Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on Linkedin:
”For decades, oral protein delivery has failed.
Jan Astermark at the BIC meeting 2025 presented comprehensive information on oral factor VIII bispecific treatment for haemophilia A – potentially the first oral FVIII mimetic treatment!
Why is this so groundbreaking?
For decades, oral protein delivery has failed due to three major barriers:
- Large molecular size (poor absorption/bioavailability)
- GI instability (narrow pH tolerance, variable factors)
- High hydrophilicity (can’t cross membrane barriers)
This innovative Inno8 approach systematically addresses each challenge: ✨
- Optimized size (~30 kDa) via albumin binding technology
- Enhanced stability through protraction and pH optimization
- SNAC absorption enhancement for membrane permeability
- Extended half-life (115h terminal half-life!)
- Once-daily dosing potential with reduced variability
Inno8 successfully balances all critical aspects for an oral hemophilia drug – Size ✓ Potency ✓Stability ✓ PK ✓ – currently advancing through Phase 1 clinical trials for both patients with and without inhibitors.”
Stay updated on all coming congresses and seminars in the field of bleeding disorders with Hemostasis Today.
-
Sep 30, 2025, 11:43Wolfgang Miesbach: Jan Astermark at the BIC 2025 Presented Potentially the First Oral FVIII Mimetic Treatment for Hemophilia A
-
Sep 30, 2025, 06:43Sara García Barcenilla: What Better Way to Celebrate ''World ITP Day'' Then With The Interview of Nora Butta and Daniel Aníbal García-Diego
-
Sep 30, 2025, 06:42Courtney Battaglia: AFib Can Cause Racing Heartbeat or Fatigue and Also Raises The Risk of Stroke!
-
Sep 29, 2025, 22:44Pall T. Onundarson on Correlation Between Plasma Levels of DOACs and Both Thromboembolic and Bleeding Events
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 30, 2025, 06:45Robert Mikulik and Colleagues Show Differences in Acute Ischemic Stroke Treatment
-
Sep 30, 2025, 06:40Cihan Ay: Can AI Match Thrombosis Experts?
-
Sep 29, 2025, 19:56Luisa Hora de Carvalho and Colleagues Highlight The Challenges in Evaluating Thromboembolic Risk in Acute Leukemia
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 11:48Nan van Geloven on Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 19:39Louise Bannon: Today is World Heart Day, And It's Deeply Personal For Me
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe